2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 146 filers reported holding 2SEVENTY BIO INC in Q2 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,927,867 | -54.4% | 1,002,007 | +17.6% | 1.56% | -40.5% |
| Q2 2023 | $8,622,311 | -1.1% | 852,007 | -0.4% | 2.62% | +13.0% |
| Q1 2023 | $8,721,000 | +179.3% | 855,000 | +156.6% | 2.32% | +178.2% |
| Q4 2022 | $3,122,571 | -59.5% | 333,252 | -37.1% | 0.83% | -59.9% |
| Q3 2022 | $7,715,000 | -28.7% | 530,223 | -35.3% | 2.07% | -49.8% |
| Q2 2022 | $10,820,000 | -22.6% | 819,672 | 0.0% | 4.13% | -30.5% |
| Q1 2022 | $13,984,000 | – | 819,672 | – | 5.95% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 4,890,706 | $49,493,945 | 6.81% |
| CHI Advisors LLC | 852,007 | $8,622,311 | 2.62% |
| Casdin Capital, LLC | 2,023,913 | $20,482,000 | 1.79% |
| Newtyn Management, LLC | 737,744 | $7,465,969 | 1.76% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $14,258,078 | 1.47% |
| DAFNA Capital Management LLC | 496,416 | $5,023,730 | 1.37% |
| AlphaCentric Advisors LLC | 180,000 | $1,821,600 | 1.01% |
| SECTORAL ASSET MANAGEMENT INC | 462,485 | $4,680,348 | 0.78% |
| CLOUGH CAPITAL PARTNERS L P | 529,110 | $5,354,593 | 0.54% |
| Bleichroeder LP | 255,230 | $2,582,928 | 0.52% |